The Peptide Enforcement Wave: What Actually Happened to Every Major Vendor That Shut Down in 2025-2026

Between mid-2025 and early 2026, the research peptide market experienced the most significant regulatory contraction in its history. At least eight major vendors permanently closed. One was physically raided by federal agents. Two sets of founders faced criminal prosecution. The industry's largest supplier — doing an estimated $7.4 million in monthly sales — went dark in three sentences with no warning and no refund process for its customers.

Most of the coverage that followed was written by vendors with a financial interest in redirecting displaced customers to themselves. This article is different. We have no products to sell. We have no affiliate relationship with any vendor discussed below. Every claim in this piece comes from federal court records, FDA enforcement documentation, or independently verified reporting — all cited.

Here is what actually happened, and what it means for anyone researching peptides in 2026.

The three forces that broke the grey market simultaneously

Understanding individual vendor closures requires understanding the environment that made them inevitable. Three forces converged between 2024 and 2026 in a way that made the grey-market research peptide model structurally untenable.

Force 1 — FDA enforcement escalated from paperwork to prosecution

For years, FDA enforcement against research peptide vendors followed a predictable, survivable pattern: warning letters, requests for voluntary compliance, the occasional import alert. Companies could receive a warning letter, quietly adjust some marketing language, and continue operating. The risk was manageable.

That changed in late 2024 when the FDA sent warning letters specifically targeting vendors marketing semaglutide, tirzepatide, and retatrutide as research-use-only compounds to Prime Peptides, Xcel Peptides, SwissChems, and others. The letters were more pointed than previous enforcement communications — explicitly noting that the compounds being sold were biologically identical to FDA-approved drugs and that the research-use-only framing was not providing legal protection.

In June 2025, the era of survivable enforcement ended. FDA agents physically raided the Amino Asylum warehouse, seizing inventory and shutting down operations overnight. This was the first physical raid on a major peptide vendor. For the rest of the industry, it was a turning point. Warning letters are costly but survivable. Federal raids are not.

By September 2025, the FDA had issued more than 50 warning letters to GLP-1 compounders and vendors in a single month — a 50% year-over-year increase in enforcement actions. The message was clear: enforcement resources were being allocated at scale, and the era of selective, manageable regulatory pressure was over.

Force 2 — Pharmaceutical companies opened a second front through civil litigation

Simultaneously, the companies that manufactured FDA-approved versions of the most popular grey-market peptides began filing federal lawsuits.

In April 2025, Eli Lilly filed federal lawsuits against telehealth companies distributing unapproved tirzepatide — including Fella Health and Mochi Health — alleging trademark infringement and distribution of unapproved drugs. In August 2025, Novo Nordisk filed lawsuits against 14 defendants, including pharmacies and vendors compounding or distributing semaglutide products.

These companies have effectively unlimited legal budgets. The message to any vendor carrying GLP-1 compounds was simple: every sale created potential liability from an opponent that would never run out of money to litigate.

Adding legislative weight to the corporate legal pressure, the SAFE Drugs Act (H.R. 6509) was introduced in early 2026 — a bipartisan bill that would explicitly prohibit the sale of research chemicals biologically identical to FDA-approved drugs without a New Drug Application. The "research use only" legal shield that had protected the entire industry for a decade was, in the words of healthcare law firm Frier Levitt, providing "essentially zero protection" by the time the bill was introduced.

Force 3 — Independent testing made quality failures visible and public

At the same time that regulatory and legal pressure was mounting, independent third-party testing platforms began systematically documenting product quality failures at major vendors in a way that was publicly accessible and searchable.

Finnrick Analytics tested dozens of products from the industry's largest vendors and published the results. The findings were damaging for some of the market's most trusted names. Products that had been marketed on reputation rather than documentation began failing against objective quality standards. When testing failures became public, they removed the quality credibility that might otherwise have justified continued operations despite regulatory risk.

The closures — what happened at each vendor, sourced from the record

Amino Asylum — FDA warehouse raid, June 2025

What happened: In June 2025, FDA agents conducted a physical raid on Amino Asylum's warehouse. The site went offline overnight, payment processing was terminated, and pending orders were frozen with no communication to customers.

Why: Multiple contributing factors documented in enforcement records. Amino Asylum had received prior FDA warning letters that it did not adequately address. The company had been marketing products in ways that blurred the line between research chemicals and consumer health products. It sold prescription-only medications alongside peptides and SARMs. It used trademarked pharmaceutical brand names in marketing materials. The raid came after the company had essentially dared regulators to act.

Scale: Amino Asylum had an estimated 400,000+ monthly website visitors and was one of the five most-searched peptide vendors in the United States at the time of closure.

Customer impact: No warning, no order fulfillment, no refund process. Customers with pending orders were left without recourse outside of credit card chargebacks.

Significance: This was the enforcement action that changed the industry's risk calculus. A physical warehouse raid demonstrated that the FDA was willing to move beyond warning letters to operational disruption. Every major vendor operating after June 2025 knew that ignoring regulatory pressure was no longer a viable strategy.

Paradigm Peptides — federal criminal prosecution, December 2025

What happened: Founders Matthew Kawa and Jennifer Stechkober pleaded guilty to federal charges on December 10, 2025. The website now displays a closure notice. Kawa's sentencing was scheduled for March 24, 2026.

Why: Federal investigators determined that products sold and labeled as SARMs actually contained testosterone — a Schedule III controlled substance. Additional charges related to selling unapproved drugs including peptides, hCG, and SARMs without FDA authorization. This was not a marketing violation or a labeling technicality. The company was selling misidentified controlled substances.

Significance: This case established that selling mislabeled research compounds could result in criminal prosecution and potential prison time — not just civil penalties or warning letters. It followed the Tailor Made Compounding prosecution, which had resulted in a $1.79 million forfeiture, and All American Peptide, whose owners pleaded guilty to conspiracy charges involving over $3 million in forfeitures. By the time Paradigm's founders entered their guilty pleas, the criminal prosecution pathway was an established reality.

Science.bio — voluntary closure, January 2026

What happened: Science.bio announced its permanent closure on January 27, 2026, just six weeks before Peptide Sciences shut down.

Why: No official explanation was given beyond the voluntary framing. Science.bio had been a well-regarded vendor in the nootropics and research chemical space. The timing — one week after the industry-wide enforcement escalation and immediately following the Paradigm Peptides guilty pleas — strongly suggests a preemptive regulatory exit rather than a business failure.

Customer impact: Unlike some closures, Science.bio gave customers advance notice, allowing time to complete or cancel pending orders.

Peptide Sciences — voluntary closure, March 6, 2026

What happened: At approximately 2:00 PM Eastern on March 6, 2026, visitors to peptidesciences.com were met with a three-sentence statement. The company had voluntarily decided to shut down operations and discontinue all product sales. No advance warning. No guidance for customers with pending orders. No refund process.

Scale: Peptide Sciences was generating an estimated $7.4 million in monthly online sales as of December 2025, according to e-commerce analytics firm Grips Intelligence. The site drew approximately 990,000 monthly visitors. It had operated for over a decade. It was the default vendor for a significant portion of the research peptide community.

Why: Three converging forces, documented in the public record.

First, regulatory exposure. The company had already received at least one FDA warning letter around 2023. After the Amino Asylum raid and the Paradigm Peptides guilty pleas, continued operations represented existential legal risk. Shutting down voluntarily is legally far less damaging than being raided or prosecuted — the company appears to have made the calculation that walking away was preferable to waiting for enforcement to arrive.

Second, pharmaceutical litigation exposure. Peptide Sciences carried both semaglutide and tirzepatide in its catalog. These were among its most popular products. After Eli Lilly and Novo Nordisk filed federal lawsuits against vendors and compounders in 2025, every sale of a GLP-1 compound created potential liability from companies with unlimited litigation budgets.

Third, quality failures. Independent testing platform Finnrick Analytics documented serious product quality issues at Peptide Sciences. BPC-157 scored an A rating — performing well. But CJC-1295 received an E rating with an average of 4.3 out of 10 across tested samples. Tesamorelin received an E. Most significantly, retatrutide — across 37 tested samples collected between December 2024 and March 2026 — received a failing E rating, with a counterfeit detection flagged in November 2025. For a company whose market position rested heavily on reputation as the quality option in a crowded market, these results were operationally damaging beyond their direct commercial impact.

The word "voluntarily" in the shutdown notice does significant work. A voluntary closure is legally far less damaging than an FDA-ordered shutdown or criminal prosecution. The company chose to exit on its own terms rather than wait for something worse.

Customer impact: No refund process. No guidance on pending orders. All customer support channels went silent within hours. Any website currently claiming to sell Peptide Sciences products is fraudulent — the company confirmed it has not authorized any successor operation. Credit card chargebacks remain the primary recourse for customers with unfulfilled orders.

Royal Research, Peptide Tech Labs, American Research Labs, Unchained Compounds — additional closures, 2025

At least four additional vendors closed during 2025 without the public documentation that accompanied the larger cases. Royal Research, Peptide Tech Labs, American Research Labs, and Unchained Compounds all ceased operations during this period. Several smaller vendors disappeared without any public announcement.

The pattern across these closures is consistent: the combination of escalating enforcement risk, pharmaceutical litigation exposure on GLP-1 products, and the criminal prosecution precedents established by Paradigm Peptides and others made continued operations a calculation that an increasing number of operators concluded was not worth making.

What the enforcement wave actually means for researchers — the honest assessment

The "research use only" shield is gone

The legal framework that allowed grey-market peptide vendors to operate for a decade was a specific interpretation: selling compounds labeled as research-use-only, not for human consumption, was not the same as selling unapproved drugs. This interpretation was always legally fragile, and enforcement decisions in 2025-2026 confirmed it does not hold.

The SAFE Drugs Act, if enacted, would codify this directly — explicitly prohibiting the sale of research chemicals that are biologically identical to FDA-approved drugs without a New Drug Application. Even without the legislation, the FDA's enforcement posture and pharmaceutical company litigation have already produced the same practical effect for the compounds that matter most.

The vendors that survived are, on balance, more trustworthy than those that closed

This is genuinely good news for researchers, even if it arrived via disruption. The enforcement wave functioned as an involuntary quality filter. Vendors that operated with documented third-party testing, genuine research-only positioning, and transparent business practices were dramatically underrepresented in enforcement actions. The vendors that survived did so because they were already operating closer to what the regulatory environment requires.

The legal pathway is actually improving simultaneously

The closures happened alongside a genuine regulatory improvement that is easy to miss. On February 27, 2026, HHS Secretary RFK Jr. announced that approximately 14 of the 19 peptides the FDA had restricted in 2023 would be moved back to Category 1, restoring the compounding pharmacy pathway with a physician's prescription. On April 15, 2026, the FDA formalized this by removing 12 peptides from Category 2 and announcing the July 23-24 PCAC hearing.

The compounds are not disappearing. They are moving behind a regulatory wall — accessible through licensed channels with medical oversight, rather than through direct-to-consumer grey-market sales. For researchers who can access the licensed pathway, this is an improvement: pharmaceutical-grade quality controls, accurate dosing, endotoxin testing, and legal accountability.

The risk environment for remaining vendors is not resolved

Vendors operating in the research peptide space in 2026 are doing so in a fundamentally different risk environment than existed two years ago. The enforcement infrastructure is built, the prosecution precedents are established, and the pharmaceutical company litigation model is proven. Any vendor carrying GLP-1 analogs faces ongoing exposure. The market has consolidated, but the underlying legal tensions that drove consolidation have not been resolved.

How to evaluate vendors in the current environment

Given everything documented above, these are the questions that actually matter when evaluating a research peptide vendor in 2026 — not marketing language, not price, not Reddit reputation.

Does every product page link to a batch-specific third-party certificate of analysis? Not a generic COA, not an in-house test, not "available on request." The COA should be linked on the product page, from a named independent lab (Janoshik Analytical, MZ Biolabs, or Colmaric Analyticals), and tied to a specific lot number.

Is the vendor US-based with a verifiable physical address and business entity? Anonymous operations have no accountability. Legitimate research businesses are registered entities with real addresses.

Does the vendor carry GLP-1 analogs (semaglutide, tirzepatide, retatrutide) as research compounds? If yes, understand that these products carry the highest regulatory and litigation exposure of any compounds in this market right now. That exposure extends to any vendor prominently carrying them.

How long has the vendor been operating? Vendors that appeared in 2026 after the Peptide Sciences closure should be evaluated with significant caution — some exist specifically to capture displaced customers with no track record behind them.

ThePeptide.expert maintains a Price Index tracking 16 verified, currently operating vendors with third-party COA documentation — updated monthly. See the Price Index for current pricing data and vendor verification status. Peptides frequently referenced in this piece include BPC-157, TB-500, and Semax.